COHEN & STEERS INC (CNS) Fundamental Analysis & Valuation
NYSE:CNS • US19247A1007
Current stock price
69.15 USD
+1 (+1.47%)
Last:
This CNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CNS Profitability Analysis
1.1 Basic Checks
- In the past year CNS was profitable.
- In the past year CNS has reported a negative cash flow from operations.
- CNS had positive earnings in each of the past 5 years.
- Of the past 5 years CNS 4 years had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of CNS (17.48%) is better than 92.89% of its industry peers.
- With an excellent Return On Equity value of 27.27%, CNS belongs to the best of the industry, outperforming 91.21% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 20.96%, CNS belongs to the best of the industry, outperforming 96.65% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 7.30%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.48% | ||
| ROE | 27.27% | ||
| ROIC | 20.96% |
ROA(3y)17.87%
ROA(5y)24.39%
ROE(3y)30.23%
ROE(5y)44.84%
ROIC(3y)23.28%
ROIC(5y)32.89%
1.3 Margins
- With a decent Profit Margin value of 27.66%, CNS is doing good in the industry, outperforming 67.78% of the companies in the same industry.
- In the last couple of years the Profit Margin of CNS has grown nicely.
- With a decent Operating Margin value of 31.68%, CNS is doing good in the industry, outperforming 60.25% of the companies in the same industry.
- CNS's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 86.84%, CNS belongs to the top of the industry, outperforming 91.63% of the companies in the same industry.
- In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.68% | ||
| PM (TTM) | 27.66% | ||
| GM | 86.84% |
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
2. CNS Health Analysis
2.1 Basic Checks
- Compared to 1 year ago, CNS has more shares outstanding
- CNS has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 7.79 indicates that CNS is not in any danger for bankruptcy at the moment.
- CNS's Altman-Z score of 7.79 is amongst the best of the industry. CNS outperforms 92.89% of its industry peers.
- There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.79 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 0.98 indicates that CNS may have some problems paying its short term obligations.
- CNS has a Current ratio of 0.98. This is comparable to the rest of the industry: CNS outperforms 42.68% of its industry peers.
- A Quick Ratio of 0.98 indicates that CNS may have some problems paying its short term obligations.
- CNS has a Quick ratio of 0.98. This is comparable to the rest of the industry: CNS outperforms 43.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.98 |
3. CNS Growth Analysis
3.1 Past
- The Earnings Per Share has been growing slightly by 5.37% over the past year.
- Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 3.74% on average per year.
- CNS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.16%.
- The Revenue has been growing slightly by 5.73% on average over the past years.
EPS 1Y (TTM)5.37%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%5.33%
Revenue 1Y (TTM)9.16%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%8.31%
3.2 Future
- The Earnings Per Share is expected to grow by 7.32% on average over the next years.
- Based on estimates for the next years, CNS will show a small growth in Revenue. The Revenue will grow by 3.01% on average per year.
EPS Next Y10.23%
EPS Next 2Y10.78%
EPS Next 3Y3.87%
EPS Next 5Y7.32%
Revenue Next Year4.19%
Revenue Next 2Y4.28%
Revenue Next 3Y-0.11%
Revenue Next 5Y3.01%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. CNS Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 22.02, which indicates a rather expensive current valuation of CNS.
- Compared to the rest of the industry, the Price/Earnings ratio of CNS indicates a slightly more expensive valuation: CNS is more expensive than 64.02% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.15, CNS is valued at the same level.
- Based on the Price/Forward Earnings ratio of 18.18, the valuation of CNS can be described as rather expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of CNS is on the same level as its industry peers.
- When comparing the Price/Forward Earnings ratio of CNS to the average of the S&P500 Index (22.12), we can say CNS is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.02 | ||
| Fwd PE | 18.18 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CNS indicates a somewhat cheap valuation: CNS is cheaper than 69.87% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 17.93 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The decent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)2.15
PEG (5Y)5.89
EPS Next 2Y10.78%
EPS Next 3Y3.87%
5. CNS Dividend Analysis
5.1 Amount
- CNS has a Yearly Dividend Yield of 3.99%. Purely for dividend investing, there may be better candidates out there.
- CNS's Dividend Yield is comparable with the industry average which is at 6.53.
- Compared to an average S&P500 Dividend Yield of 1.82, CNS pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.99% |
5.2 History
- The dividend of CNS decreases each year by -0.61%.
- CNS has paid a dividend for at least 10 years, which is a reliable track record.
- CNS has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-0.61%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- 82.84% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP82.84%
EPS Next 2Y10.78%
EPS Next 3Y3.87%
CNS Fundamentals: All Metrics, Ratios and Statistics
NYSE:CNS (4/28/2026, 2:25:26 PM)
69.15
+1 (+1.47%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)04-16 2026-04-16/amc
Earnings (Next)07-15 2026-07-15/amc
Inst Owners56.08%
Inst Owner Change0.55%
Ins Owners22.61%
Ins Owner Change5.62%
Market Cap3.55B
Revenue(TTM)564.83M
Net Income(TTM)153.22M
Analysts48
Price Target66.3 (-4.12%)
Short Float %3.17%
Short Ratio2.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.99% |
Yearly Dividend2.5
Dividend Growth(5Y)-0.61%
DP82.84%
Div Incr Years3
Div Non Decr Years3
Ex-Date03-09 2026-03-09 (0.67)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.25%
Min EPS beat(2)-0.99%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-1.02%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)2
Avg EPS beat(8)-1.07%
EPS beat(12)4
Avg EPS beat(12)0.08%
EPS beat(16)8
Avg EPS beat(16)0.68%
Revenue beat(2)1
Avg Revenue beat(2)0.17%
Min Revenue beat(2)-0.52%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.18%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.8%
PT rev (3m)-15.58%
EPS NQ rev (1m)3.85%
EPS NQ rev (3m)3.18%
EPS NY rev (1m)1.3%
EPS NY rev (3m)1.6%
Revenue NQ rev (1m)2.09%
Revenue NQ rev (3m)1.57%
Revenue NY rev (1m)-2.89%
Revenue NY rev (3m)-3.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.02 | ||
| Fwd PE | 18.18 | ||
| P/S | 6.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.32 | ||
| P/tB | 6.56 | ||
| EV/EBITDA | 17.93 |
EPS(TTM)3.14
EY4.54%
EPS(NY)3.8
Fwd EY5.5%
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS10.78
BVpS10.94
TBVpS10.55
PEG (NY)2.15
PEG (5Y)5.89
Graham Number27.795 (-59.8%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.48% | ||
| ROE | 27.27% | ||
| ROCE | 27.12% | ||
| ROIC | 20.96% | ||
| ROICexc | 27.04% | ||
| ROICexgc | 30.2% | ||
| OM | 31.68% | ||
| PM (TTM) | 27.66% | ||
| GM | 86.84% | ||
| FCFM | N/A |
ROA(3y)17.87%
ROA(5y)24.39%
ROE(3y)30.23%
ROE(5y)44.84%
ROIC(3y)23.28%
ROIC(5y)32.89%
ROICexc(3y)33.62%
ROICexc(5y)61.08%
ROICexgc(3y)38.82%
ROICexgc(5y)75.29%
ROCE(3y)30.11%
ROCE(5y)42.55%
ROICexgc growth 3Y-33.24%
ROICexgc growth 5Y-15.16%
ROICexc growth 3Y-30.82%
ROICexc growth 5Y-13.86%
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
F-Score3
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 51.04% | ||
| Cap/Sales | 1.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 7.79 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)421.2%
Cap/Depr(5y)277.41%
Cap/Sales(3y)4.98%
Cap/Sales(5y)3.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.37%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%5.33%
EPS Next Y10.23%
EPS Next 2Y10.78%
EPS Next 3Y3.87%
EPS Next 5Y7.32%
Revenue 1Y (TTM)9.16%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%8.31%
Revenue Next Year4.19%
Revenue Next 2Y4.28%
Revenue Next 3Y-0.11%
Revenue Next 5Y3.01%
EBIT growth 1Y1.51%
EBIT growth 3Y-4.78%
EBIT growth 5Y3.6%
EBIT Next Year0.51%
EBIT Next 3Y0.2%
EBIT Next 5Y5.6%
FCF growth 1Y-248.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-224.57%
OCF growth 3YN/A
OCF growth 5YN/A
COHEN & STEERS INC / CNS Fundamental Analysis FAQ
What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CNS.
What is the valuation status for CNS stock?
ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.
What is the profitability of CNS stock?
COHEN & STEERS INC (CNS) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for CNS stock?
The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 22.02 and the Price/Book (PB) ratio is 6.32.
What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?
The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 10.23% in the next year.